Haemophilus influenzae type b

Haemophilus influenzae type b. It is a serotype of the bacterium Haemophilus influenzae and was historically a leading cause of serious invasive bacterial infections in young children worldwide. The organism is a small, Gram-negative, pleomorphic coccobacillus that requires specific growth factors, notably hemin (X factor) and NAD+ (V factor). Prior to the development of effective conjugate vaccines, it was a predominant cause of bacterial meningitis, epiglottitis, pneumonia, and other life-threatening conditions in the pediatric population.

Microbiology and classification

The bacterium is classified within the family Pasteurellaceae and the genus Haemophilus. It is a fastidious organism requiring enriched media like chocolate agar supplemented with X and V factors for isolation. Differentiation from other Haemophilus influenzae serotypes (a through f) and non-typeable strains is based on the presence of a distinct polysaccharide capsule, specifically composed of polyribosylribitol phosphate (PRP). This capsule is a major virulence factor and the primary target for vaccine development. The organism can be identified in the laboratory through capsular swelling (Quellung reaction) with specific antisera, agglutination tests, or polymerase chain reaction (PCR) assays.

Pathogenesis and clinical significance

Infection typically begins with colonization of the nasopharynx, followed by invasion of the bloodstream, a state known as bacteremia. The polyribosylribitol phosphate capsule confers resistance to complement-mediated phagocytosis and lysis, allowing systemic spread. This can lead to meningitis by crossing the blood-brain barrier, acute epiglottitis causing airway obstruction, septic arthritis, cellulitis, and osteomyelitis. Before the Hib vaccine, it was the most common cause of bacterial meningitis in children under five years old in the United States, often resulting in severe neurological sequelae such as hearing loss, seizure disorders, and developmental disability.

Epidemiology

Historically, the disease had a worldwide distribution, with the highest incidence in children aged 6 months to 2 years. The World Health Organization estimated it caused approximately 3 million cases of serious illness and 400,000 deaths annually in the pre-vaccine era. Certain populations, including Native American (e.g., Navajo Nation) and Alaska Native communities, experienced incidence rates many times higher than the general population. The epidemiology shifted dramatically following the introduction of conjugate vaccines in the late 1980s and early 1990s, such as those developed by Praxair's Lederle Laboratories and other manufacturers, leading to a reduction in incidence of over 99% in vaccinated populations.

Prevention and vaccination

The cornerstone of prevention is vaccination with the Hib vaccine, a conjugate vaccine that links the polyribosylribitol phosphate capsular polysaccharide to a protein carrier such as tetanus toxoid or the outer membrane protein of Neisseria meningitidis. This conjugation induces a T-cell dependent immune response, producing high-affinity IgG antibodies and immunological memory even in infants. The Centers for Disease Control and Prevention and the World Health Organization recommend incorporation into routine childhood immunization schedules, typically starting at two months of age. Widespread vaccination has led to the near-elimination of invasive disease in countries with high vaccine coverage and has also reduced nasopharyngeal carriage, inducing herd immunity.

Diagnosis and treatment

Diagnosis of invasive disease requires isolation of the bacterium from a normally sterile site such as cerebrospinal fluid, blood, or pleural fluid. Gram stain of cerebrospinal fluid may show small Gram-negative coccobacilli. Rapid antigen detection tests, like latex fixation tests for PRP, and polymerase chain reaction assays are also used. Empiric treatment for suspected invasive disease, especially meningitis, must be initiated promptly and typically involves a third-generation cephalosporin such as ceftriaxone or cefotaxime. Chloramphenicol was historically used but is now reserved for settings with limited resources or specific allergies. Dexamethasone is often administered as an adjunct therapy for meningitis to mitigate inflammatory response and reduce neurological complications.

Category:Haemophilus Category:Bacterial diseases Category:Vaccine-preventable diseases